Frattini M - Search Results

1

Role of NEU3 Overexpression in the Prediction of Efficacy of EGFR-Targeted Therapies in Colon Cancer Cell Lines.

Bovio F, Epistolio S, Mozzi A, Monti E, Fusi P, Forcella M, Frattini M. Bovio F, et al. Among authors: frattini m. Int J Mol Sci. 2020 Nov 20;21(22):8805. doi: 10.3390/ijms21228805. Int J Mol Sci. 2020. PMID: 33233823 Free PMC article.

2

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.

Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L. Frattini M, et al. Br J Cancer. 2007 Oct 22;97(8):1139-45. doi: 10.1038/sj.bjc.6604009. Epub 2007 Oct 16. Br J Cancer. 2007. PMID: 17940504 Free PMC article.

3

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O, Girlando S, Soini B, Spitale A, Di Nicolantonio F, Saletti P, Crippa S, Mazzucchelli L, Marchetti A, Bardelli A, Frattini M. Molinari F, et al. Among authors: frattini m. Clin Cancer Res. 2011 Jul 15;17(14):4901-14. doi: 10.1158/1078-0432.CCR-10-3137. Epub 2011 Jun 1. Clin Cancer Res. 2011. PMID: 21632860

4

Synthesis and biological evaluation of 1,4-diaryl-2-azetidinones as specific anticancer agents: activation of adenosine monophosphate activated protein kinase and induction of apoptosis.

Tripodi F, Pagliarin R, Fumagalli G, Bigi A, Fusi P, Orsini F, Frattini M, Coccetti P. Tripodi F, et al. Among authors: frattini m. J Med Chem. 2012 Mar 8;55(5):2112-24. doi: 10.1021/jm201344a. Epub 2012 Feb 22. J Med Chem. 2012. PMID: 22329561

5

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.

Martin V, Landi L, Molinari F, Fountzilas G, Geva R, Riva A, Saletti P, De Dosso S, Spitale A, Tejpar S, Kalogeras KT, Mazzucchelli L, Frattini M, Cappuzzo F. Martin V, et al. Among authors: frattini m. Br J Cancer. 2013 Feb 19;108(3):668-75. doi: 10.1038/bjc.2013.4. Epub 2013 Jan 24. Br J Cancer. 2013. PMID: 23348520 Free PMC article.

6

NEU3 activity enhances EGFR activation without affecting EGFR expression and acts on its sialylation levels.

Mozzi A, Forcella M, Riva A, Difrancesco C, Molinari F, Martin V, Papini N, Bernasconi B, Nonnis S, Tedeschi G, Mazzucchelli L, Monti E, Fusi P, Frattini M. Mozzi A, et al. Among authors: frattini m. Glycobiology. 2015 Aug;25(8):855-68. doi: 10.1093/glycob/cwv026. Epub 2015 Apr 28. Glycobiology. 2015. PMID: 25922362 Free article.

7

Cadmium-transformed cells in the in vitro cell transformation assay reveal different proliferative behaviours and activated pathways.

Forcella M, Callegaro G, Melchioretto P, Gribaldo L, Frattini M, Stefanini FM, Fusi P, Urani C. Forcella M, et al. Among authors: frattini m. Toxicol In Vitro. 2016 Oct;36:71-80. doi: 10.1016/j.tiv.2016.07.006. Epub 2016 Jul 16. Toxicol In Vitro. 2016. PMID: 27432484 Free article.

8

SensiScreen®KRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations.

Riva A, BØrgesen M, Guldmann-Christensen M, Hauge Kyneb M, Voogd K, Andersen C, Epistolio S, Merlo E, Yding Wolff T, Hamilton-Dutoit S, Lorenzen J, Christensen UB, Frattini M. Riva A, et al. Among authors: frattini m. PLoS One. 2017 Jun 21;12(6):e0178027. doi: 10.1371/journal.pone.0178027. eCollection 2017. PLoS One. 2017. PMID: 28636636 Free PMC article.

9

Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3.

Forcella M, Oldani M, Epistolio S, Freguia S, Monti E, Fusi P, Frattini M. Forcella M, et al. Among authors: frattini m. PLoS One. 2017 Oct 31;12(10):e0187289. doi: 10.1371/journal.pone.0187289. eCollection 2017. PLoS One. 2017. PMID: 29088281 Free PMC article.

10

The role of Piccolo in cancer treatment: relationship with EGFR and related therapies, and a marker for new targeted therapies.

Frattini M, Molinari F, Epistolio S. Frattini M, et al. J Thorac Dis. 2017 Nov;9(11):4240-4243. doi: 10.21037/jtd.2017.10.38. J Thorac Dis. 2017. PMID: 29268482 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

179 results

Search Page